{'52WeekChange': 1.0167787,
 'SandP52WeekChange': 0.0644362,
 'address1': '29 Hartwell Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 18.05,
 'askSize': 1100,
 'averageDailyVolume10Day': 1681862,
 'averageVolume': 1867647,
 'averageVolume10days': 1681862,
 'beta': 0.489554,
 'beta3Year': None,
 'bid': 18.03,
 'bidSize': 1000,
 'bookValue': 2.376,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lexington',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.54,
 'dayLow': 17.64,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -10.289,
 'enterpriseToRevenue': 90.282,
 'enterpriseValue': 991655104,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 17.884571,
 'fiftyTwoWeekHigh': 28.09,
 'fiftyTwoWeekLow': 6.8,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 38125265,
 'forwardEps': -1.55,
 'forwardPE': -11.632258,
 'fromCurrency': None,
 'fullTimeEmployees': 93,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.18091999,
 'heldPercentInstitutions': 0.86333,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/translate.bio',
 'longBusinessSummary': 'Translate Bio, Inc., a clinical-stage messenger RNA '
                        '(mRNA) therapeutics company, develops medicines to '
                        'treat diseases caused by protein or gene dysfunction. '
                        'The company is developing MRT5005, which is in Phase '
                        'I/II clinical trial for the treatment of cystic '
                        'fibrosis; and MRT5201 to treat ornithine '
                        'transcarbamylase deficiency. The company was formerly '
                        'known as RaNA Therapeutics, Inc. and changed its name '
                        'to Translate Bio, Inc. in June 2017. Translate Bio, '
                        'Inc. was founded in 2011 and is headquartered in '
                        'Lexington, Massachusetts.',
 'longName': 'Translate Bio, Inc.',
 'market': 'us_market',
 'marketCap': 1222313216,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_143808159',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -94377000,
 'nextFiscalYearEnd': 1640908800,
 'open': 18.54,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 945 7361',
 'previousClose': 18.85,
 'priceHint': 2,
 'priceToBook': 7.588384,
 'priceToSalesTrailing12Months': 111.28125,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.54,
 'regularMarketDayLow': 17.64,
 'regularMarketOpen': 18.54,
 'regularMarketPreviousClose': 18.85,
 'regularMarketPrice': 18.54,
 'regularMarketVolume': 1405703,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 67793296,
 'sharesPercentSharesOut': 0.0646,
 'sharesShort': 4063273,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1844958,
 'shortName': 'Translate Bio, Inc.',
 'shortPercentOfFloat': 0.17,
 'shortRatio': 1.45,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'TBIO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.71,
 'twoHundredDayAverage': 12.557985,
 'volume': 1405703,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.translate.bio',
 'yield': None,
 'ytdReturn': None,
 'zip': '02421'}